What one share of Avenue Therapeutics holds
Avenue Therapeutics, Inc. (“Avenue” or the “Company”) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases.
Avenue Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.00 |
|---|---|
| Profit | −$0.86 |
| Cash and investments | $0.59 |
| Book value | $0.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1,854 | — | — | — | — |
| 2020 | — | −$351.07 | — | — | — | — |
| 2021 | — | −$246.94 | — | — | — | — |
| 2024 | $0.00 | −$9.00 | — | — | — | $1.33 |
| 2025 | $0.45 | −$0.93 | — | — | — | $0.58 |
Common questions about Avenue Therapeutics
How much does one share of Avenue Therapeutics earn?
Over the last 12 months, Avenue Therapeutics lost $0.86 for each share.
Does Avenue Therapeutics pay a dividend?
Avenue Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Avenue Therapeutics’s book value per share?
Avenue Therapeutics’s book value is $0.17 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Avenue Therapeutics have?
Each share of Avenue Therapeutics has $0.59 of cash and investments, as of June 30, 2026.
Has Avenue Therapeutics bought back shares?
Avenue Therapeutics’s share count rose about 22306% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.